Non-viral delivery platforms play a crucial role in modern biopharmaceutical research, particularly in gene delivery, nucleic acid therapeutics (such as mRNA and siRNA), and protein delivery. Compared to viral vectors, non-viral systems offer advantages such as lower immunogenicity, higher controllability, and flexible manufacturing, making them a core choice in both academic and industrial development. The main non-viral delivery platforms include Lipid Nanoparticles (LNPs), Adeno-Associated Virus (AAV), and Polymer-Based Delivery Systems. Each platform has unique characteristics in terms of material composition, delivery mechanism, targeting capability, and stability, making them suitable for different research and development needs. A systematic comparison of these platforms can help researchers make informed decisions when designing experiments and selecting technical approaches.
Lipid nanoparticles are nano-scale carriers constructed from lipid materials and are widely used for nucleic acid delivery. LNPs typically consist of four key components: ionizable lipids, structural lipids, cholesterol, and PEGylated lipids.
Key Features and Advantages:
High delivery efficiency: LNPs can effectively encapsulate RNA or DNA molecules, protect nucleic acids from degradation, and facilitate cellular uptake and endosomal escape.
Tunable targeting: By adjusting lipid composition and surface modifications, LNPs can achieve tissue-specific delivery, such as liver targeting.
Low immunogenicity: Compared to viral vectors, LNPs trigger minimal immune responses, allowing for repeated dosing.
Scalable manufacturing: Microfluidic and self-assembly technologies enable industrial-scale production with consistent batch quality.
Applications:
LNPs are widely applied in mRNA vaccines, siRNA therapeutics, and protein delivery, making them a preferred platform for short nucleic acids and protein molecules.
Limitations:
Delivery efficiency can be limited in certain tissues (e.g., lung or heart). Particle stability is sensitive to environmental pH, ionic strength, and storage conditions.
AAV is a non-pathogenic viral vector that, in the context of non-viral delivery discussions, is often considered a semi-non-viral system because it does not rely on self-replication and can achieve efficient gene delivery. AAV is known for its small, stable capsid structure and multiple serotypes with tissue specificity.
Key Features and Advantages:
High tissue specificity: Different serotypes enable efficient targeting of the liver, muscle, nervous system, and other tissues.
Long-term expression: Even as a non-integrating vector, AAV can achieve stable expression of exogenous genes.
Low cytotoxicity: Compared to some viral vectors, AAV induces relatively mild immune responses.
Applications:
AAV is suitable for studies requiring sustained gene expression, such as gene function validation, in vivo transfection, and protein expression studies.
Limitations:
Limited cargo capacity (typically ≤5 kb), posing challenges for large genes. Higher production costs and process complexity, which may restrict industrial scalability and rapid iteration.
Polymer-based delivery systems are constructed from synthetic or natural polymers and can be used for nucleic acids, proteins, and small molecule drugs. Common types include cationic polymers (e.g., polyethyleneimine, PEI), natural polysaccharides (e.g., chitosan), and biodegradable polyesters (e.g., PLGA).
Key Features and Advantages:
High tunability: Altering polymer structure, molecular weight, and functional group modifications allows precise control of drug loading, release rate, and targeting.
Biodegradability: Most polymers degrade gradually in vivo, reducing long-term accumulation and toxicity.
Versatile delivery strategies: Polymers can form nanoparticles, micelles, or hydrogels, enabling localized or systemic delivery.
Applications:
Polymer carriers are commonly used in laboratory research, gene transfection, protein sustained release, and combination delivery strategies. They are an important platform for exploring new delivery systems and material optimization.
Limitations:
Compared to LNPs and AAV, cellular delivery efficiency may be lower, requiring formulation and process optimization. High concentrations of cationic polymers may induce cytotoxicity, necessitating a balance between safety and performance.
Fig.1 LNP vs AAV vs Polymers delivery platform comparison (BOC Sciences Original).
Non-viral delivery platforms show significant differences in composition and assembly mechanisms. LNPs are typically composed of ionizable lipids, structural lipids, cholesterol, and PEGylated lipids, forming stable nanoparticles through self-assembly. AAV, as a semi-non-viral system, consists of a protein capsid encapsulating single-stranded DNA with a highly ordered structure. Polymer-based delivery systems are assembled from cationic polymers, natural polysaccharides, or biodegradable polyesters, forming particles or micelles via molecular interactions that control stability and morphology.
| Delivery Platform | Main Components | Assembly Mechanism | Key Features |
| LNP | Ionizable lipids, structural lipids, cholesterol, PEGylated lipids | Self-assembly into nanoparticles | Adjustable lipid ratios for high stability and targeting |
| AAV | Protein capsid, single-stranded DNA | Protein self-assembly into viral capsid | Highly ordered structure, natural nucleic acid protection |
| Polymer-based | Cationic polymers, natural polysaccharides, biodegradable polyesters | Electrostatic and hydrophobic interactions forming particles/micelles | Highly tunable, allows sustained release and combination delivery |
Particle size and surface properties directly affect biodistribution, cellular uptake, and stability. LNPs typically range from 50 to 150 nm, and surface charge and hydrophilicity can be adjusted through lipid composition and PEGylation. AAV particles are approximately 20–25 nm, with fixed surface charge determined by capsid proteins, providing tissue specificity. Polymer-based carriers have a wide size range from tens to hundreds of nanometers, with surface charge, hydrophobicity, and functional ligands tunable through chemical modification.
| Delivery Platform | Size Range | Surface Charge | Tunability | Stability |
| LNP | 50–150 nm | Adjustable positive/neutral | High, via lipid ratio and PEGylation | Moderate, sensitive to storage conditions |
| AAV | 20–25 nm | Fixed, mainly negative | Low, depends on serotype | High, natural capsid provides protection |
| Polymer-based | 30–500 nm | Adjustable positive/negative/neutral | High, via chemical modification | Adjustable, depends on polymer type and environment |
BOC Sciences delivers payload-specific LNP formulation and process optimization services engineered for mRNA, siRNA, and advanced nucleic acid constructs.
Delivery efficiency and release capability are core performance indicators. LNPs achieve efficient cellular uptake and nucleic acid release through membrane fusion and endosomal escape. AAV mediates endocytosis and nuclear transport via capsid–receptor interactions, enabling stable gene expression. Polymer-based carriers rely on electrostatic interactions or stimulus-responsive degradation for cellular uptake and payload release, with efficiency dependent on formulation optimization.
| Delivery Platform | Uptake Mechanism | Endosomal Release | Expression/Release Duration | Advantages |
| LNP | Membrane fusion, endocytosis | High | Short to medium term | High delivery efficiency, repeatable dosing |
| AAV | Receptor-mediated endocytosis | Moderate | Long-term stable | Sustained gene expression, high tissue specificity |
| Polymer-based | Electrostatic adsorption/endocytosis | Moderate, tunable via degradation | Controlled release possible | Flexible design, compatible with various molecules |
Payload compatibility varies across platforms for nucleic acids, proteins, and small molecules. LNPs are most suitable for short RNA or DNA molecules. Polymer-based carriers can accommodate a wide range of molecules and support combination delivery. AAV is limited by gene size (≤5 kb) but suitable for small to medium-length genes.
| Delivery Platform | Nucleic Acid Compatibility | Protein Compatibility | Small Molecule Compatibility | Maximum Payload | Suitable Applications |
| LNP | High | Moderate | Moderate | Suitable for short RNA/DNA | Nucleic acid therapeutics, vaccines |
| AAV | Moderate | Low | Low | ≤5 kb DNA | Sustained gene expression studies |
| Polymer-based | High | High | High | Adjustable | Basic research, combination delivery, sustained release systems |
Preparation methods determine controllability and batch consistency. LNPs are typically produced via microfluidic self-assembly or emulsification, with mature and tunable processes. AAV relies on cell culture and capsid protein expression, with complex procedures and strict production requirements. Polymer-based carriers have diverse preparation methods, including self-assembly, solvent precipitation, and nanoemulsification, optimized according to material and carrier type.
| Delivery Platform | Preparation Method | Process Complexity | Controllability | Flexibility |
| LNP | Microfluidics, emulsification | Moderate | High | High, adjustable through components |
| AAV | Cell culture, capsid protein expression | High | Moderate | Low, limited by production conditions |
| Polymer-based | Self-assembly, solvent precipitation, nanoemulsification | Low to moderate | High | High, can be designed for specific payloads |
For industrial production, scalability and batch consistency affect usability and stability. LNPs are easy to scale up with high batch consistency. AAV production is costly and scale-up is challenging, requiring strict control of cell culture and purification processes. Polymer-based carriers can achieve scalable production through chemical synthesis and process optimization, though batch variations may occur depending on polymer type.
| Delivery Platform | Scale-Up Difficulty | Batch Consistency | Process Maturity | Industrial Potential |
| LNP | Low | High | High | High, suitable for industrial production |
| AAV | High | Moderate | Moderate | Moderate, production limited |
| Polymer-based | Moderate | Moderate | High | High, adjustable based on material |
Unlike AAV, which relies on the limited space of viral capsids, or polymer-based carriers with relatively uniform structures, LNPs provide a highly programmable and engineering-driven delivery platform. The precise controllability of their physicochemical properties, combined with strong reproducibility in industrial manufacturing, positions LNPs as a preferred solution for increasingly complex therapeutic formulations.
The engineering foundation of LNPs lies in the modular design of their components. By precisely adjusting the ratios of four key lipid components, nanoparticle surface charge, size distribution, and endosomal escape efficiency can be finely controlled.
Compared with the strict payload size limitations of AAV, typically below 4.7 kb, LNPs demonstrate substantially greater engineering flexibility in payload capacity and protection.
During the transition from laboratory development to large-scale production, LNPs demonstrate superior industrial compatibility compared with polymer-based systems and viral vectors.
We have established a science-driven service framework focused on delivering high-performance non-viral delivery solutions through precise chemical engineering and fluid dynamics-based design. Our capabilities are structured to support systematic optimization and reproducible engineering of LNP delivery systems.
The performance of LNPs is highly dependent on the synergistic interactions among individual lipid components. We provide customized formulation screening and optimization services to achieve optimal biodistribution profiles and expression efficiency.
Different nucleic acid cargos impose distinct physicochemical requirements on the internal LNP environment. We perform cargo-guided engineering optimization to ensure compatibility and stability.
From microgram-scale screening to kilogram-scale production, we provide process development support based on controlled fluid dynamics to ensure performance consistency during scale-up.
Comprehensive analytical characterization is essential for assessing LNP quality and predicting delivery behavior. We provide multidimensional quality benchmarking using advanced analytical platforms.
Table 7. BOC Sciences Comprehensive LNP Development Services.
References
